chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Haemoglobin decreased, Hyperkalaemia, Prohormone brain natriuretic peptide increased, Pulmonary congestion
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/30/21 (EN6205 Pfizer Dose 2 4/20/21 (EM9809) COVID Positive 11/22/21  11/22/21: Patient is a 91 year male from home and recently discharged. He presents to the ER today with complaints of shortness of breath and generalized weakness. Patient's past medical history significant with CKD 3, diastolic CHF, anemia of CKD hyperlipidemia, hypertension and Hashimoto thyroiditis. Patient is fully vaccinated for COVID-19.  He had stable vital signs upon arrival to the ER. Chest x-ray showed cardiomegaly with mild pulmonary venous congestion and early pulmonary edema.  Blood work in ER showed proBNP 4305, creatinine 1.5, troponin positive x1 and hemoglobin 8.2. Patient was treated with 40 mg IV 1 time, aspirin and Nitro-Bid. Patient was transfer to the medical unit.   I met with the patient and the he was resting in bed and denies any discomfort at this time. Patient is currently 2 L oxygen nasal cannula with sats around 92%. Patient denies fever chills, abdominal pain, constipation, chest pain, palpitation, dizziness, headaches. Patient will be admitted and treated for CHF at exacerbation. And discussed the plan of care with the patient and she is agreeable to stay for further management. Patient reports having a caregiver twice a week  11/29/21: Patient is a 91 year male from home who presents to the ER today with complaints of shortness of breath and generalized weakness. Patient's past medical history significant with CKD 3, diastolic CHF, anemia of CKD hyperlipidemia, hypertension and Hashimoto thyroiditis. Patient is fully vaccinated for COVID-19.  He had stable vital signs upon arrival to the ER. Chest x-ray showed cardiomegaly with mild pulmonary venous congestion and early pulmonary edema. Blood work in ER showed proBNP 4305, creatinine 1.5, troponin positive x1 and hemoglobin 8.2. Patient was treated with 40 mg IV 1 time, aspirin and Nitro-Bid. Patient was transfer to the medical unit and treated for CHF exacerbation, Covid 19  pneumonia, acute kidney injury and hyperkalemia. He was treated with Remdesivir, dexamethasone and IV antibiotics. Nephrology was consulted for AKI and hyperkalemia. The patient's symptoms improved and he was able to transfer to Allure in Moline for skills nursing. Today patient denies fever chills, abdominal pain, constipation, chest pain, palpitation, dizziness, and headaches. he has stable vitals and will be transferred by EMS services.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary oedema, SARS-CoV-2 test positive, Troponin, Vaccine breakthrough infection
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/30/21 (EN6205 Pfizer Dose 2 4/20/21 (EM9809) COVID Positive 11/22/21  11/22/21: Patient is a 91 year male from home and recently discharged. He presents to the ER today with complaints of shortness of breath and generalized weakness. Patient's past medical history significant with CKD 3, diastolic CHF, anemia of CKD hyperlipidemia, hypertension and Hashimoto thyroiditis. Patient is fully vaccinated for COVID-19.  He had stable vital signs upon arrival to the ER. Chest x-ray showed cardiomegaly with mild pulmonary venous congestion and early pulmonary edema.  Blood work in ER showed proBNP 4305, creatinine 1.5, troponin positive x1 and hemoglobin 8.2. Patient was treated with 40 mg IV 1 time, aspirin and Nitro-Bid. Patient was transfer to the medical unit.   I met with the patient and the he was resting in bed and denies any discomfort at this time. Patient is currently 2 L oxygen nasal cannula with sats around 92%. Patient denies fever chills, abdominal pain, constipation, chest pain, palpitation, dizziness, headaches. Patient will be admitted and treated for CHF at exacerbation. And discussed the plan of care with the patient and she is agreeable to stay for further management. Patient reports having a caregiver twice a week  11/29/21: Patient is a 91 year male from home who presents to the ER today with complaints of shortness of breath and generalized weakness. Patient's past medical history significant with CKD 3, diastolic CHF, anemia of CKD hyperlipidemia, hypertension and Hashimoto thyroiditis. Patient is fully vaccinated for COVID-19.  He had stable vital signs upon arrival to the ER. Chest x-ray showed cardiomegaly with mild pulmonary venous congestion and early pulmonary edema. Blood work in ER showed proBNP 4305, creatinine 1.5, troponin positive x1 and hemoglobin 8.2. Patient was treated with 40 mg IV 1 time, aspirin and Nitro-Bid. Patient was transfer to the medical unit and treated for CHF exacerbation, Covid 19  pneumonia, acute kidney injury and hyperkalemia. He was treated with Remdesivir, dexamethasone and IV antibiotics. Nephrology was consulted for AKI and hyperkalemia. The patient's symptoms improved and he was able to transfer to Allure in Moline for skills nursing. Today patient denies fever chills, abdominal pain, constipation, chest pain, palpitation, dizziness, and headaches. he has stable vitals and will be transferred by EMS services.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by  COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 8.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product preparation error
Clinical narrative: vaccine was not reconstituted prior to giving - no known adverse effects.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Dyspnoea, Respiratory rate increased, Throat tightness
Clinical narrative: During prescreening questions stated that she had a reaction to her Pfizer covid vaccine the first time but not the second time. She said that she had a hard time breathing but the medical staff where she got the vaccine (previously) did not do anything to treat this and said it was just anxiety. Was to wait 30 mins after the vaccine to make sure she doesn?t have a reaction. During that time, medical staff  went to sit down next to her periodically to make sure she was okay. During the observation time, they noticed that she was breathing a little faster. Administered the auto inject .3mL epi pen in her left thigh at 1542. She had hives to her extremities prior to injection. Administered another .3mL of the epi at 1547 (5 mins after 1st dose), after the patient stated she felt her throat was still tight and that she was still having trouble breathing. EMS arrived 1 min after the second epi administration and they assessed the patient. The medics arrived about 3 mins after that and assessed the patient.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by  COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Hyperventilation, Pallor, Respiration abnormal, Tremor
Clinical narrative: About 2-3 minutes after receiving vaccine, patient became a little dizzy, wash visibly shaky, and face went pale. She was also hyperventilating a little. She mentioned her vision was starting to go dark around the edges. Patient was seated at this time. Her mother alerted us right away, we grabbed the emergency use bag and went out to monitor her.  Patient was responsive and we observed no swelling or trouble breathing. Patient mentioned she could breathe fine as well. Pharmacist had patient count her breathing (4 sec inhale, hold 4 seconds, 4 sec exhale, hold 4 sec), while instructing a coworker to grab a cold water. Patient was wearing a smart watch that showed her pulse, so pharmacist was keeping an eye on that as well (in the few minutes we were with her the highest pulse pharmacist saw was 78). We administered a dose of benadryl 50m to the patient at mother's request. Once the patient's breathing returned to normal (about 2-3 more minutes) the color came back to her face. Had patient wait about 15 more minutes, after symptoms resolved before letting them leave the store.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Visual impairment
Clinical narrative: About 2-3 minutes after receiving vaccine, patient became a little dizzy, wash visibly shaky, and face went pale. She was also hyperventilating a little. She mentioned her vision was starting to go dark around the edges. Patient was seated at this time. Her mother alerted us right away, we grabbed the emergency use bag and went out to monitor her.  Patient was responsive and we observed no swelling or trouble breathing. Patient mentioned she could breathe fine as well. Pharmacist had patient count her breathing (4 sec inhale, hold 4 seconds, 4 sec exhale, hold 4 sec), while instructing a coworker to grab a cold water. Patient was wearing a smart watch that showed her pulse, so pharmacist was keeping an eye on that as well (in the few minutes we were with her the highest pulse pharmacist saw was 78). We administered a dose of benadryl 50m to the patient at mother's request. Once the patient's breathing returned to normal (about 2-3 more minutes) the color came back to her face. Had patient wait about 15 more minutes, after symptoms resolved before letting them leave the store.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 6.0
Sex: M
Vaccine: COVID19
Symptoms: Product preparation error
Clinical narrative: No reported adverse events as of now.  Patient received an undiluted dose of the Pediatric Pfizer Covid vaccine
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Patient was 12 years old and received the dose for the 5-11 year olds - no adverse effects.
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: patient hospitalized
Age: 0.33
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Respiratory tract congestion
Clinical narrative: 5/16/2022 case went for his routine dialysis treatment. The next day, 05/17 he began feeling extremely week, fatigued and congested. Case went to hospital on 05/18 and was admitted for 2 days. Case was given monoclonal antibody treatment and is beginning to feel better.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 4.0
Sex: M
Vaccine: MMRV
Symptoms: Pain, Swelling
Clinical narrative: local swelling and pain
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 33.0
Sex: F
Vaccine: UNK
Symptoms: Chest pain, Dyspnoea, Echocardiogram abnormal, Electrocardiogram abnormal, Electrocardiogram ambulatory normal
Clinical narrative: Af episode 10 days after the second dose Abnormal ecg, rise in septal to 20 mm in echocardiogram  Anterior and inferior infract 30 days after second dose Chest pain, shortness of breath, rise in troponin enzyme Af episodes cleaned after 8 months and the pain is gone We are going to check the echocardiogram again The patient was af free at 48 holter monitoring
Age: 33.0
Sex: F
Vaccine: UNK
Symptoms: Infarction, Troponin increased
Clinical narrative: Af episode 10 days after the second dose Abnormal ecg, rise in septal to 20 mm in echocardiogram  Anterior and inferior infract 30 days after second dose Chest pain, shortness of breath, rise in troponin enzyme Af episodes cleaned after 8 months and the pain is gone We are going to check the echocardiogram again The patient was af free at 48 holter monitoring
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 60.0
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 91.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 92.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by state for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Underdose
Clinical narrative: Patient was to receive his first dose of the COVID-19 Moderna vaccine; however, was given the booster dose - no adverse effects.  Note: The vaccine site was not documented (although it was likely the left arm, as subsequent doses were in the left arm).
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Decreased appetite, Dyspnoea exertional, Fall
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/24/21 (EN6204) Pfizer Dose 2 4/22/21 (EW0151) COVID Positive 12/18/21  12/18/21: History is obtained from patient as well as by personal review of records. Patient started feeling congested and fatigued 6 days ago.  He also had generalized weakness, loss of appetite, intermittent vomiting, fever, body aches.  He reports dyspnea on exertion.  Was sent from convenient Care to emergency department.  He tested positive for   SARS-CoV-2.   He has taken  SARS-CoV-2 mRNA vaccinations in March and April 2021.  The patient states that he has been taking a baby aspirin daily.  He denies any other blood thinner use.  He does have history of paroxysmal atrial fibrillation as well as hypothyroidism.  He takes a statin for cholesterol.  History of mechanical fall on 12/17/2021.  Sustained injury to finger on right hand  12/20/21: Follow-up PCP, Patient Discharge Condition Stable; Discharged; Instructions and Education material given to patient;  Remain in isolation until 10 days after positive COVID test.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Inappropriate schedule of product administration, Limb injury, Pain, Pyrexia
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/24/21 (EN6204) Pfizer Dose 2 4/22/21 (EW0151) COVID Positive 12/18/21  12/18/21: History is obtained from patient as well as by personal review of records. Patient started feeling congested and fatigued 6 days ago.  He also had generalized weakness, loss of appetite, intermittent vomiting, fever, body aches.  He reports dyspnea on exertion.  Was sent from convenient Care to emergency department.  He tested positive for   SARS-CoV-2.   He has taken  SARS-CoV-2 mRNA vaccinations in March and April 2021.  The patient states that he has been taking a baby aspirin daily.  He denies any other blood thinner use.  He does have history of paroxysmal atrial fibrillation as well as hypothyroidism.  He takes a statin for cholesterol.  History of mechanical fall on 12/17/2021.  Sustained injury to finger on right hand  12/20/21: Follow-up PCP, Patient Discharge Condition Stable; Discharged; Instructions and Education material given to patient;  Remain in isolation until 10 days after positive COVID test.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory tract congestion, SARS-CoV-2 test positive, Vaccine breakthrough infection, Vomiting
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/24/21 (EN6204) Pfizer Dose 2 4/22/21 (EW0151) COVID Positive 12/18/21  12/18/21: History is obtained from patient as well as by personal review of records. Patient started feeling congested and fatigued 6 days ago.  He also had generalized weakness, loss of appetite, intermittent vomiting, fever, body aches.  He reports dyspnea on exertion.  Was sent from convenient Care to emergency department.  He tested positive for   SARS-CoV-2.   He has taken  SARS-CoV-2 mRNA vaccinations in March and April 2021.  The patient states that he has been taking a baby aspirin daily.  He denies any other blood thinner use.  He does have history of paroxysmal atrial fibrillation as well as hypothyroidism.  He takes a statin for cholesterol.  History of mechanical fall on 12/17/2021.  Sustained injury to finger on right hand  12/20/21: Follow-up PCP, Patient Discharge Condition Stable; Discharged; Instructions and Education material given to patient;  Remain in isolation until 10 days after positive COVID test.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Acute left ventricular failure, Asthenia, COVID-19, COVID-19 pneumonia, Cardiac failure congestive
Clinical narrative: CovId Vaccine Breakthrough Case  Moderna Dose 1 2/19/21 (031L20A) Moderna Dose 2 3/19/21 (013A21A) COVID Positive 12/19/21  12/19/21: History is mostly obtained by personal review of records. He is 80-year-old gentleman with known history of congestive heart failure, ejection fraction 25-30%, chronic kidney disease, insulin-dependent diabetes mellitus, pulmonary embolism and other medical problems.  Was having cough, subjective fever and generalized weakness for 10 days.  He tested positive for  SARS-CoV-2. Complaints of severe generalized weakness.  Having good pulse ox on 2 L oxygen.  Denied chest pain.  12/24/21: The patient is 80-year-old male with  history of 25-30%, CKD, insulin-dependent diabetes, SVT amiodarone, pulmonary embolism, AICD placement and other medical problems. Patient presents to the ER on 12/19/2021 with complaints of generalized weakness and fall. Patient tested himself with over-the-counter COVID-19 and reportedly was positive. Patient fell at home and was found on the ground. He denied losing consciousness and head trauma. Patient was noted at that time with low oxygen saturation 91% room air therefore EMT place him supplemental oxygen. He was then taken to the ER for further evaluation. Upon arrival to the ER patient was back to his baseline mentation. Patient was admitted into the medical unit and treated with bilateral COVID 19 pneumonia, and acute systolic CHF.  Patient was treated with remdesivir, dexamethasone, and IV antibiotic. His symptoms improved and patient was able to work with physical therapy who recommended skilled nursing. Patient received insurance approval and will be transferred to Allure.  Patient's wife who is his primary caretaker was informed about the plan.  Patient is being discharged in improved and stable condition. All questions were answered and patient to transfer through EMS.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Cough, Fall, Oxygen saturation decreased, Pyrexia
Clinical narrative: CovId Vaccine Breakthrough Case  Moderna Dose 1 2/19/21 (031L20A) Moderna Dose 2 3/19/21 (013A21A) COVID Positive 12/19/21  12/19/21: History is mostly obtained by personal review of records. He is 80-year-old gentleman with known history of congestive heart failure, ejection fraction 25-30%, chronic kidney disease, insulin-dependent diabetes mellitus, pulmonary embolism and other medical problems.  Was having cough, subjective fever and generalized weakness for 10 days.  He tested positive for  SARS-CoV-2. Complaints of severe generalized weakness.  Having good pulse ox on 2 L oxygen.  Denied chest pain.  12/24/21: The patient is 80-year-old male with  history of 25-30%, CKD, insulin-dependent diabetes, SVT amiodarone, pulmonary embolism, AICD placement and other medical problems. Patient presents to the ER on 12/19/2021 with complaints of generalized weakness and fall. Patient tested himself with over-the-counter COVID-19 and reportedly was positive. Patient fell at home and was found on the ground. He denied losing consciousness and head trauma. Patient was noted at that time with low oxygen saturation 91% room air therefore EMT place him supplemental oxygen. He was then taken to the ER for further evaluation. Upon arrival to the ER patient was back to his baseline mentation. Patient was admitted into the medical unit and treated with bilateral COVID 19 pneumonia, and acute systolic CHF.  Patient was treated with remdesivir, dexamethasone, and IV antibiotic. His symptoms improved and patient was able to work with physical therapy who recommended skilled nursing. Patient received insurance approval and will be transferred to Allure.  Patient's wife who is his primary caretaker was informed about the plan.  Patient is being discharged in improved and stable condition. All questions were answered and patient to transfer through EMS.